The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Australia backs Pfizer virus vaccine over AstraZeneca for under-50s

Thu, 08th Apr 2021 02:20

* Policy shift will hold up vaccination campaign, says PM

* People with first shot should still get their second

* Italy, UK have suggested AstraZeneca shot age limits
(Adds quote from chief health officer, prime minister and adds
detail)

By Colin Packham and Jonathan Barrett

CANBERRA/SYDNEY, April 8 (Reuters) - Australia said on
Thursday it now recommends people under 50 should get Pfizer's
COVID-19 vaccine in preference to AstraZeneca's
shot, a policy shift that it warned would hold up its
inoculation campaign.

The move, a day after European regulators reiterated they
had found possible links between AstraZeneca's shot and reports
of very rare cases of blood clots, is a huge hurdle for
Australia's programme, which had relied on that vaccine.

Australia's Chief Medical Officer, Paul Kelly, told
reporters the risk of clots was extremely low.

"It's only been found in the first dose of the AstraZeneca
vaccine, usually within 4 to 10 days after that vaccine. But it
is serious, and it can cause up to a 25% death rate when it
occurs," he said.

Australia would advise health providers to only give a first
dose of the AstraZeneca vaccine to adults younger than 50 when
the benefit clearly outweighs the risks, he added.

Italy and Britain on Wednesday joined other countries in
suggesting age limits for AstraZeneca's vaccine. But the
European regulators reaffirmed the importance of that shot in
protecting people against COVID-19.

Those who have already had a first AstraZeneca dose without
any serious adverse events "can safely be given their second
dose," Kelly said.

Prime Minister Scott Morrison said the updated advice will
delay Australia's inoculation timetable, but it was too soon to
say when Canberra would now vaccinate its adult population.

"There will be a recalibration of how the programme will
need to be adjusted," Morrison told reporters in Canberra.

Australia has ordered 20 million doses of the Pfizer vaccine
and Morrison said Canberra was in talks to increase the order.

Authorities will continue to give the AstraZeneca vaccine to
people over 70. Those over 50 who opt for the Pfizer vaccine
will have to wait, the government said.

Australia - which had planned to use the AstraZeneca vaccine
for the vast majority of its near 26 million population -
expected to give all adults at least one shot by October.

But its immunisation campaign was already heavily behind
schedule.

It had pledged to administer at least 4 million first doses
by the end of March, but could only deliver 670,000, with the
government blaming the delay on supply issues in Europe.

It had been looking to ramp up the immunisation effort,
underpinned by plans to make 50 million doses of AstraZeneca
vaccine in Australia, produced by CSL Ltd.

Australia began vaccinations much later than some other
nations because of its few infections, which stand at just under
29,400, with 909 deaths, since the pandemic began.

(Global vaccination tracker: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/vaccination-rollout-and-access/)

(Interactive graphic tracking global spread of coronavirus:
https://graphics.reuters.com/world-coronavirus-tracker-and-maps/)

(Reporting by Colin Packham and Jonathan Barrett; Editing by
Michael Perry, Clarence Fernandez and Andrew Heavens)

More News
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.